Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biotech deals
Biotech
Moderna exits Metagenomi gene editing deal worth $3B biobucks
Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting a partnership worth up to $3 billion in biobucks.
Gabrielle Masson
May 1, 2024 4:00pm
Harmony buys Epygenix for $35M upfront
Apr 30, 2024 10:04am
Novartis pays PeptiDream $180M as radiopharma big bang continues
Apr 30, 2024 4:12am
BMS pays $65M to expand Repertoire of autoimmune assets
Apr 29, 2024 6:15am
Regeneron signs Mammoth gene editing deal worth $100M upfront
Apr 25, 2024 8:49am
To be better at neuroscience, Biogen will invest elsewhere
Apr 24, 2024 10:37am